Last reviewed · How we verify
NCT07311577
Disitamab Vedotin Combined With Platinum and Bevacizumab as First-Line and Maintenance Therapy for HER2-Expressing, HRD-Negative High-Risk Ovarian Cancer: A Multicenter, Non-Randomized, Single-Arm Phase II Clinical Study
Phase 2 trial testing RC48+Carboplatin+Bevacizumab in Ovarian Cancer Metastatic in 43 participants. Currently enrolling.
30 December 2027
Quick facts
| Lead sponsor | Jiangsu Cancer Institute & Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 43 |
| Start date | 1 January 2026 |
| Primary completion | 30 December 2027 |
| Estimated completion | 30 December 2028 |
| Sites | 2 locations across China |
Drugs / interventions tested
- RC48+Carboplatin+Bevacizumab — full drug profile →
Conditions studied
- Ovarian Cancer Metastatic — all drugs for Ovarian Cancer Metastatic →
- Ovarian Cancer Metastatic Recurrent — all drugs for Ovarian Cancer Metastatic Recurrent →
Sponsor
Jiangsu Cancer Institute & Hospital
Who can join
Adults 18 to 75, any sex, with Ovarian Cancer Metastatic or Ovarian Cancer Metastatic Recurrent. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a prospective, multicenter, phase II study designed to evaluate the efficacy and safety of disitamab vedotin combined with platinum plus bevacizumab as first-line therapy for HER2-expressing, HRD-negative high-risk ovarian cancer. Forty-three patients with pathologically confirmed HRD-negative high-risk ovarian cancer will be enrolled. After enrollment, patients will receive disitamab vedotin plus platinum and bevacizumab as first-line and maintenance treatment. First-line phase: Carboplatin AUC 5 intravenously on Day 1 every 21 days over 1 h ,Bevacizumab 7.5-15 mg/kg intravenously on Day 1 every 21 days over 30-90 min. Maintenance phase: Patients who achieve response (CR or PR) will continue disitamab vedotin monotherapy plus bevacizumab (investigator decides whether to continue disitamab vedotin and for how long). Maintenance duration: bevacizumab until disease progression or up to 22 cycles; disitamab vedotin up to 6 months (8 cycles).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07311577
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ovarian Cancer Metastatic
Currently open trials in the same condition.
- NCT07009743 — O-RADS MRI System on Early Detection of Ovarian Cancer · active not recruiting
Other Jiangsu Cancer Institute & Hospital trials
Trials by the same sponsor.
- NCT07408609 — Perioperative Chemotherapy With Low-Dose Radiotherapy and Tislelizumab for Locally Advanced Gastric or Gastroesophageal · Phase 2 · not yet recruiting
- NCT07407452 — Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Che · Phase 2 · not yet recruiting
- NCT07446387 — A Clinical Study of Iparomlimab and Tuvonralimab Combined With Bevacizumab and Alternating Triweekly CAPOX/mCAPIRI Regim · Phase 2 · not yet recruiting
- NCT05912582 — Prospective Study for Molecular Biomarkers and Spatial Transcriptomics of Nasopharyngeal Carcinoma · not yet recruiting
- NCT07286942 — Stereotactic Body Radiotherapy With Sequential Iparomlimab and Tuvonralimab (QL1706) + Chemotherapy as Neoadjuvant Thera · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07311577 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Jiangsu Cancer Institute & Hospital
- Last refreshed: 31 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07311577.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing